We're Here for You!
The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.
In this week’s blog, IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie thoroughly discusses details on Tecvayli (teclistamab-cqyv)— a new bispecific antibody that was recently approved by the FDA for the treatment of relapsed or refractory multiple myeloma (RRMM). He delves into overall findings from the MajesTEC-1 Trial; in-hospital step-up dose schedule for teclistamab treatments; as well as follow-up treatment and supportive care. READ THE BLOG.
The International Myeloma Foundation (IMF) today announced it has been selected as a winner of the 2022 Amazon Web Services (AWS) IMAGINE Grant, a public grant opportunity open to registered 501(c) nonprofit organizations in the United States who are using technology to solve the world’s most pressing challenges. The grant will support the IMF’s efforts to use cloud technology to educate patients, unlock donor insights, increase fundraising, and more. LEARN MORE.
On November 22, 2022, GSK announced it has initiated the process for withdrawal of the U.S. marketing authorization for Blenrep (belantamab mafadotin-blmf) following the request of the U.S Food and Drug administration (FDA). This request was based upon the previously announced outcome of the DREAMM-3 phase III confirmatory trial which did not meet the requirements of the FDA Accelerated Approval regulations. Read the full update here.
The speakers for this webinar were Jens Hillengass, MD, PhD (Roswell Park Comprehensive Cancer Center, Buffalo, NY) and IMF Nurse Leadership Board member Beth Faiman, PhD, MSN, APRN-BC, AOCN®, FAAN (Cleveland Clinic – Taussig Cancer Institute). They review why bone health is so important in myeloma, provide tips on living well with myeloma bone disease, give guidelines for physical activity, and more. WATCH THE REPLAY.
This IMF Patient and Family Webinar focuses on “Understanding the New Myeloma Landscape.” The speakers for this event include IMF Chairman of the Board and Chief Scientific Officer Brian G.M. Durie; S. Vincent Rajkumar, MD (Mayo Clinic – Rochester, MN); Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN (Cleveland Clinic – Taussig Cancer Institute); and Alfred L. Garfall, MD, MS (University of Pennsylvania – Philadelphia). There is a special focus on new immune therapies, including Tecvayli™ (teclistamab-cqyv), as well as available clinical trials. WATCH THE REPLAY.
Need assistance in creating a fundraiser? The IMF team is here for you. Find out how you can help in the fight against myeloma today!